Home  |  Contact

Cellosaurus XMMME-001 (CVCL_F817)

[Text version]

Cell line name XMMME-001
Synonyms IND1
Accession CVCL_F817
Resource Identification Initiative To cite this cell line use: XMMME-001 (RRID:CVCL_F817)
Comments Group: Patented cell line.
Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8759.
Biotechnology: The monoclonal antibody produced by this hybridoma was conjugated to a ricin chain A to produce XomaZyme-Mel (XMMME-001-RTA) which was evaluated in several clinical trials for metastatic melanoma patients (DOI=10.3390/antib1010039).
Monoclonal antibody isotype: IgG2a.
Monoclonal antibody target: Human melanoma tumor specific HMW antigen.
Species of origin Mus musculus (Mouse) (NCBI Taxonomy: 10090)
Hierarchy Parent: CVCL_3411 (P3X63Ag8)
Category Hybridoma
Publications

PubMed=6609971
Kernan N.A., Knowles R.W., Burns M.J., Broxmeyer H.E., Lu L., Lee H.M., Kawahata R.T., Scannon P.J., Dupont B.
Specific inhibition of in vitro lymphocyte transformation by an anti-pan T cell (gp67) ricin A chain immunotoxin.
J. Immunol. 133:137-146(1984)

Patent=US4590071
Scannon P.J., Spitler L.E., Lee H.M., Kawahata R.T., Mischak R.P.
Human melanoma specific immunotoxins.
Patent number US4590071, 20-May-1986

DOI=10.3390/antib1010039
Becker N., Benhar I.
Antibody-based immunotoxins for the treatment of cancer.
Antibodies 1:39-69(2012)

Cross-references
Cell line collections ATCC; HB-8759
Cell line databases/resources CLO; CLO_0009652
Encyclopedic resources Wikidata; Q54994849
Entry history
Entry creation11-Feb-2013
Last entry update23-Sep-2021
Version number5